It’s countdown to showtime for five emerging life science firms that believe their businesses are worth investment from outside backers.
BioKier, CanDiag, Improved Patient Outcomes, KinoDyn, and Nova Synthetix will each get a chance to pitch potential investors during the “Innovation Showcase” at the Council for Entrepreneurial Development’s annual Life Science Conference on Feb. 26.
Each firm will have 10 minutes to make their case.
A snapshot of each firm as provided by CED:
- BioKier is developing a small-molecule oral therapeutic for treatment of diabetes, designed to mimic the effect of bariatric weight-loss surgery without the physical trauma and cost of surgery.
- CanDiag has a worldwide exclusive license to a patented tumor antibody that has been used to develop a blood test for the early detection of breast cancer.
- Improved Patient Outcomes (IPO), a joint venture between Duke University and mobile health firm CellepathicRx, uses technology to send patients messages about tendencies associated with 75 diseases.
- KinoDyn is a cancer diagnostic and drug discovery company built on a proprietary UNC-CH technology using multiplexed inhibitor beads and mass spectroscopy.
- Nova synthetix, a biotechnology company, is using castor to create a non -polluting, renewable feedstock for chemicals and biofuels.
“These are some of the most promising early stage companies in North Carolina,” said Dhruv Patel, CED’s Program Director. “Because the future of healthcare rests on the advancements of today’s technology, CED is pleased to provide these companies with a platform to present their innovations at one of our most exciting conferences.”
The two-day conference on Feb. 26-27 is scheduled at the Raleigh Convention Center. It is put on by CED in partnership with NCBIO, and the NC Biotechnology Center.
